The role of gut endocrine cells in control of metabolism and appetite

Experimental Physiology

Volumn 99, Issue 9, 2014, Pages 1116-1120

  Parker, Helen E ^a   Gribble, Fiona M ^a   Reimann, Frank ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; PROTEIN FOS;

ARCUATE NUCLEUS; AREA POSTREMA; ARTICLE; ENTEROENDOCRINE CELL; FOOD INTAKE; GLUCAGON RELEASE; GLUCOSE METABOLISM; HORMONE ACTION; HORMONE RELEASE; HUMAN; INTESTINE MOTILITY; LIMBIC SYSTEM; METABOLIC REGULATION; NONHUMAN; NUCLEUS ACCUMBENS; PANCREAS ISLET ALPHA CELL; REWARD; SENSORY NERVE CELL; SPINAL CORD NERVE CELL; SPINAL GANGLION; STOMACH EMPTYING; STOMACH SECRETION; VENTRAL TEGMENTUM; ANIMAL; BRAIN; EATING; ENERGY METABOLISM; FEEDING BEHAVIOR; GASTROINTESTINAL TRACT; INNERVATION; METABOLISM; NERVE TRACT; OBESITY; PATHOPHYSIOLOGY; PSYCHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APPETITE REGULATION; BRAIN; EATING; ENERGY METABOLISM; ENTEROENDOCRINE CELLS; FEEDING BEHAVIOR; GASTROINTESTINAL TRACT; GLUCAGON-LIKE PEPTIDE 1; HUMANS; NEURAL PATHWAYS; OBESITY; SIGNAL TRANSDUCTION;

EID: 84908288694     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2014.079764     Document Type: Article

References (29)

1. 3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044, 127-131.
2. Bucinskaite V, Tolessa T, Pedersen J, Rydqvist B, Zerihun L, Holst JJ & Hellström PM (2009). Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil 21, 978-978.
3. Daly DM, Park SJ, Valinsky WC & Beyak MJ (2011). Impaired intestinal afferent nerve satiety signalling and vagal afferent excitability in diet induced obesity in the mouse. J Physiol 589, 2857-2870.
4. de Heer J, Rasmussen C, Coy DH & Holst JJ (2008). Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51, 2263-2270.
5. Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H & Skibicka KP (2012). The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J Neurosci 32, 4812-4820.
6. Dockray GJ (2013). Enteroendocrine cell signalling via the vagus nerve. Curr Opin Pharmacol 13, 954-958.
7. Dockray GJ & Burdyga G (2011). Plasticity in vagal afferent neurones during feeding and fasting: mechanisms and significance. Acta Physiol (Oxf) 201, 313-321.
8. Dossat AM, Diaz R, Gallo L, Panagos A, Kay K & Williams DL (2013). Nucleus accumbens GLP-1 receptors influence meal size and palatability. Am J Physiol Endocrinol Metab 304, E1314-E1320.
9. Duca FA, Swartz TD, Sakar Y & Covasa M (2013). Decreased intestinal nutrient response in diet-induced obese rats: role of gut peptides and nutrient receptors. Int J Obes (Lond) 37, 375-381.
10. Edholm T, Degerblad M, Grybäck P, Hilsted L, Holst JJ, Jacobsson H, Efendic S, Schmidt PT & Hellström PM (2010). Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterol Motil 22, 1191-1200, e1315.
11. Egerod KL, Engelstoft MS, Grunddal KV, Nøhr MK, Secher A, Sakata I, Pedersen J, Windeløv JA, Füchtbauer EM, Olsen J, Sundler F, Christensen JP, Wierup N, Olsen JV, Holst JJ, Zigman JM, Poulsen SS & Schwartz TW (2012). A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology 153, 5782-5795.
12. Ezcurra M, Reimann F, Gribble FM & Emery E (2013). Molecular mechanisms of incretin hormone secretion. Curr Opin Pharmacol 13, 922-927.
13. Habib AM, Richards P, Cairns LS, Rogers GJ, Bannon CA, Parker HE, Morley TC, Yeo GS, Reimann F & Gribble FM (2012). Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 153, 3054-3065.
14. Hisadome K, Reimann F, Gribble FM & Trapp S (2010). Leptin directly depolarizes preproglucagon neurons in the nucleus tractus solitarius: electrical properties of glucagon-like peptide 1 neurons. Diabetes 59, 1890-1898.
15. 1-adrenoceptor-mediated increase in glutamatergic synaptic inputs. Diabetes 60, 2701-2709.
16. Hunter K & Hölscher C (2012). Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neuroscience 13, 33.
17. Kastin AJ, Akerstrom V & Pan W (2002). Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 18, 7-14.
18. Llewellyn-Smith IJ, Reimann F, Gribble FM & Trapp S (2011). Preproglucagon neurons project widely to autonomic control areas in the mouse brain. Neuroscience 180, 111-121.
19. Mietlicki-Baase EG, Ortinski PI, Rupprecht LE, Olivos DR, Alhadeff AL, Pierce RC & Hayes MR (2013). The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors. Am J Physiol Endocrinol Metab 305, E1367-E1374.
20. Mortensen K, Christensen LL, Holst JJ & Orskov C (2003). GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 114, 189-196.
21. Pyke C, Heller RS, Kirk RK, Ørskov C, Reedtz-Runge S, Kaastrup P, Hvelplund A, Bardram L, Calatayud D & Knudsen LB (2014). GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155, 1280-1290.
22. Richards P, Parker HE, Adriaenssens AE, Hodgson JM, Cork SC, Trapp S, Gribble FM & Reimann F (2013). Identification and characterization of glucagon-like peptide-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63, 1224-1233.
23. Schirra J, Houck P, Wank U, Arnold R, Göke B & Katschinski M (2000). Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 46, 622-631.
24. Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M & Göke B (2009). GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol Motil 21, 609-618, e621-602.
25. Shirazi RH, Dickson SL & Skibicka KP (2013). Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward. PLoS One 8, e61965.
26. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K & Egan JM (2006). Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 290, E550-E559.
27. Washington MC, Raboin SJ, Thompson W, Larsen CJ & Sayegh AI (2010). Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor. Brain Res 1344, 124-133.
28. Williams DL, Baskin DG & Schwartz MW (2009). Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150, 1680-1687.
29. Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ & Elmquist JK (2003). Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23, 2939-2946.